

Certificate of Analysis

Print Date: Nov 20th 2012

www.tocris.com

Product Name: Salmeterol xinafoate


Catalog No.: 4712 Batch No.: 1


CAS Number: IUPAC Name: 94749-08-3

Name: 4-Hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2naphthalenecarboxylic acid salt

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: Batch Molecular Weight: Physical Appearance: Solubility: C₂₅H₃₇NO₄.C₁₁H₈O₃ 603.75 White solid DMSO to 100 mM ethanol to 20 mM Desiccate at RT





2. ANALYTICAL DATA

HPLC: ¹H NMR: Mass Spectrum: Microanalysis: Shows 99.7% purity Consistent with structure Consistent with structure

	Carbon	Hydrogen	Nitrogen
Theoretical	71.62	7.51	2.32
Found	71.28	6.95	2.43

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

 Corris Bioscience is an R&D Systems company

 USA & CANADA Tel: (800) 343-7475
 EUROPE Tel: +44 (0)1235 529449
 CHINA Tel: +86 (21) 52380373

 www.RnDSystems.com
 www.RnDSystems.com



)('R h

Product Name: Salmeterol xinafoate

Catalog No.: 4712 Batch No.: 1

CAS Number: **IUPAC Name:** 94749-08-3

4-Hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2naphthalenecarboxylic acid salt

Description:


Long-acting β_2 adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D₂, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD).

Physical and Chemical Properties:

Batch Molecular Formula: C₂₅H₃₇NO₄.C₁₁H₈O₃ Batch Molecular Weight: 603.75 Physical Appearance: White solid

Minimum Purity: >99%

Batch Molecular Structure:



Storage: Desiccate at RT

Solubility & Usage Info:

DMSO to 100 mM ethanol to 20 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Roberts et al (1999) The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur.Respir.J. 14 275. PMID: 10515401.

Rennard et al (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care Med. 163 1087. PMID: 11316640.

Akabane et al (2006) Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol.Int. 55 387. PMID: 17130681.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



www.tocris.com